Suppr超能文献

相似文献

1
Chromothriptic cure of WHIM syndrome.
Cell. 2015 Feb 12;160(4):686-699. doi: 10.1016/j.cell.2015.01.014. Epub 2015 Feb 5.
2
3
Mechanisms of Sustained Neutrophilia in Patient WHIM-09, Cured of WHIM Syndrome by Chromothripsis.
J Clin Immunol. 2018 Jan;38(1):77-87. doi: 10.1007/s10875-017-0457-8. Epub 2017 Nov 24.
4
Cxcr4-haploinsufficient bone marrow transplantation corrects leukopenia in an unconditioned WHIM syndrome model.
J Clin Invest. 2018 Aug 1;128(8):3312-3318. doi: 10.1172/JCI120375. Epub 2018 Jun 25.
6
Chromothriptic cure of WHIM syndrome: Implications for bone marrow transplantation.
Rare Dis. 2015 Aug 11;3(1):e1073430. doi: 10.1080/21675511.2015.1073430. eCollection 2015.
8
9
WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.
Blood. 2012 Jul 5;120(1):181-9. doi: 10.1182/blood-2011-12-395608. Epub 2012 May 17.
10
Enhancement of stem cell engraftment on a WHIM.
J Clin Invest. 2018 Aug 1;128(8):3240-3242. doi: 10.1172/JCI121857. Epub 2018 Jun 25.

引用本文的文献

1
Chromothripsis.
Methods Mol Biol. 2025;2968:3-33. doi: 10.1007/978-1-0716-4750-9_1.
2
Mavorixafor, CXCR4 antagonist, a novel treatment for WHIM syndrome, first FDA approval 2024.
Ann Med Surg (Lond). 2025 Feb 7;87(4):1777-1779. doi: 10.1097/MS9.0000000000003030. eCollection 2025 Apr.
3
4
Heterogeneous phenotype of a Chinese Familial WHIM syndrome with CXCR4 gain-of-function mutation.
Front Immunol. 2024 Nov 7;15:1460990. doi: 10.3389/fimmu.2024.1460990. eCollection 2024.
5
WBP1L regulates hematopoietic stem cell function and T cell development.
Front Immunol. 2024 Nov 1;15:1421512. doi: 10.3389/fimmu.2024.1421512. eCollection 2024.
6
Xolremdi (Mavorixafor): a breakthrough in WHIM syndrome treatment - unraveling efficacy and safety in a rare disease frontier.
Ann Med Surg (Lond). 2024 Sep 24;86(11):6381-6385. doi: 10.1097/MS9.0000000000002590. eCollection 2024 Nov.
8
Increased Susceptibility of WHIM Mice to Papillomavirus-induced Disease is Dependent upon Immune Cell Dysfunction.
PLoS Pathog. 2024 Sep 3;20(9):e1012472. doi: 10.1371/journal.ppat.1012472. eCollection 2024 Sep.
9
The complex nature of CXCR4 mutations in WHIM syndrome.
Front Immunol. 2024 Jul 5;15:1406532. doi: 10.3389/fimmu.2024.1406532. eCollection 2024.
10
Chromothripsis is a novel biomarker for prognosis and differentiation diagnosis of pancreatic neuroendocrine neoplasms.
MedComm (2020). 2024 Jul 10;5(7):e623. doi: 10.1002/mco2.623. eCollection 2024 Jul.

本文引用的文献

1
The genome editing toolbox: a spectrum of approaches for targeted modification.
Curr Opin Biotechnol. 2014 Dec;30:87-94. doi: 10.1016/j.copbio.2014.06.005. Epub 2014 Jul 8.
2
CRISPR/Cas9 for genome editing: progress, implications and challenges.
Hum Mol Genet. 2014 Sep 15;23(R1):R40-6. doi: 10.1093/hmg/ddu125. Epub 2014 Mar 20.
3
A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.
Blood. 2014 Apr 10;123(15):2308-16. doi: 10.1182/blood-2013-09-527226. Epub 2014 Feb 12.
5
Genetics on a WHIM.
Br J Haematol. 2014 Jan;164(1):15-23. doi: 10.1111/bjh.12574. Epub 2013 Sep 20.
6
Criteria for inference of chromothripsis in cancer genomes.
Cell. 2013 Mar 14;152(6):1226-36. doi: 10.1016/j.cell.2013.02.023.
7
TALENs: a widely applicable technology for targeted genome editing.
Nat Rev Mol Cell Biol. 2013 Jan;14(1):49-55. doi: 10.1038/nrm3486. Epub 2012 Nov 21.
8
Chromothripsis: chromosomes in crisis.
Dev Cell. 2012 Nov 13;23(5):908-17. doi: 10.1016/j.devcel.2012.10.010.
10
Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice.
Blood. 2012 Jun 14;119(24):5722-30. doi: 10.1182/blood-2012-01-403378. Epub 2012 Mar 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验